UCB backs epilepsy-focused digital heath startup Nile AIBelgian drugmaker UCB has been steadily building its digital health expertise for several years, and that includes nurturing Share XUCB backs epilepsy-focused digital heath startup Nile AIhttps://pharmaphorum.com/news/ucb-backs-epilepsy-focused-digital-heath-startup-nile-ai/
Amgen’s Enbrel heads ICER list of unjustified US price risesUS cost effectiveness watchdog ICER found 10 examples of substantial price rises for top-selling medicines in 2019, and Share XAmgen’s Enbrel heads ICER list of unjustified US price riseshttps://pharmaphorum.com/news/icer-lists-top-unjustified-drug-price-rises-headed-by-amgens-enbrel/
UCB revs up its gene therapy drive with Handl acquisitionUCB has made a new foray into the gene therapy space, buying fellow Belgium-based company Handl to get Share XUCB revs up its gene therapy drive with Handl acquisitionhttps://pharmaphorum.com/news/ucb-revs-up-its-gene-therapy-drive-with-handl-acquisition/
Roche doubles down on tau for Alzheimer’s, licensing UCB drug for $120mRoche already has one Alzheimer’s candidate in its pipeline targeting tau, but has added a second via a Share XRoche doubles down on tau for Alzheimer’s, licensing UCB drug for $120mhttps://pharmaphorum.com/news/roche-doubles-down-on-tau-for-alzheimers-licensing-ucb-drug-for-120m/
UCB’s IL-17 latecomer bimekizumab beats Cosentyx in psoriasis trialBelgian biopharma company UCB is bringing up the rear of the IL-17 inhibitor category with its bimekizumab drug, Share XUCB’s IL-17 latecomer bimekizumab beats Cosentyx in psoriasis trialhttps://pharmaphorum.com/news/ucbs-il-17-latecomer-bimekizumab-beats-cosentyx-in-psoriasis-trial/
Failed trial puts future of UCB’s epilepsy drug padsevonil in doubtShares in UCB slid this morning after the Belgian company announced its refractory epilepsy drug candidate padsevonil had Share XFailed trial puts future of UCB’s epilepsy drug padsevonil in doubthttps://pharmaphorum.com/news/failed-trial-puts-future-of-ucbs-epilepsy-drug-padsevonil-in-doubt/
UCB’s James Musick on embracing digital therapeuticsDigital has rapidly taken over the pharma industry, but many still don’t fully understand how to harness it. Share XUCB’s James Musick on embracing digital therapeuticshttps://pharmaphorum.com/views-analysis-digital/ucbs-james-musick-on-embracing-digital-therapeutics/
Janssen trials ultrasound-guided approach to treating Crohn’sIn the highly competitive market for inflammatory diseases such as Crohn’s, pharma companies are looking for ways to Share XJanssen trials ultrasound-guided approach to treating Crohn’shttps://pharmaphorum.com/news/janssen-trials-ultrasound-guided-approach-to-treating-crohns/
UCB/Amgen’s Evenity approved in Europe after appealUCB and Amgen’s osteoporosis drug Evenity has finally been approved in Europe, following a successful appeal against a Share XUCB/Amgen’s Evenity approved in Europe after appealhttps://pharmaphorum.com/news/ucb-amgens-evenity-approved-in-europe-after-appeal/
